{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:18:47Z","timestamp":1790327927415,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.revmed.2019.03.329","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T16:54:11Z","timestamp":1556038451000},"page":"433-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Actualit\u00e9s dans le syndrome de Sj\u00f6gren primitif\u00a0: aspects cliniques et th\u00e9rapeutiques"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-0733","authenticated-orcid":false,"given":"G.","family":"Nocturne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 11","key":"10.1016\/j.revmed.2019.03.329_bib0355","first-page":"S9","article-title":"Autoimmune epitheliitis: Sj\u00f6gren's syndrome","volume":"12","author":"Skopouli","year":"1994","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.revmed.2019.03.329_bib0360","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/rheumatology\/kev200","article-title":"Characterization of systemic disease in primary Sj\u00f6gren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements","volume":"54","author":"Ramos-Casals","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.revmed.2019.03.329_bib0365","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.rdc.2008.08.009","article-title":"Relationship of Sj\u00f6gren's syndrome to other connective tissue and autoimmune disorders","volume":"34","author":"Theander","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"issue":"5","key":"10.1016\/j.revmed.2019.03.329_bib0370","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/rheumatology\/keu400","article-title":"Clinical characteristics of RA patients with secondary SS and association with joint damage","volume":"54","author":"Brown","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.revmed.2019.03.329_bib0375","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/kes374","article-title":"Characteristics of Sj\u00f6gren's syndrome in rheumatoid arthritis","volume":"52","author":"He","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0380","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1136\/annrheumdis-2014-206860","article-title":"Is primary Sj\u00f6gren's syndrome an orphan disease? A critical appraisal of prevalence studies in Europe","volume":"74","author":"Cornec","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.revmed.2019.03.329_bib0385","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.revmed.2019.03.329_bib0390","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016\u00a0American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0395","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ajo.2009.09.013","article-title":"A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sj\u00f6gren's Syndrome International Registry","volume":"149","author":"Whitcher","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0400","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.revmed.2015.10.341","article-title":"Apport de l\u2019echographie des glandes salivaires dans la prise en charge du syndrome de Sjogren\u00a0: ou en sommes-nous\u00a0?","volume":"37","author":"Cornec","year":"2016","journal-title":"Rev Med Interne"},{"issue":"1","key":"10.1016\/j.revmed.2019.03.329_bib0405","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13075-017-1475-x","article-title":"Comparison of 2002\u00a0AECG and 2016\u00a0ACR\/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sj\u00f6gren's syndrome","volume":"19","author":"Le Goff","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0410","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/ard.2004.022707","article-title":"B cell MALT lymphoma diagnosed by labial minor salivary gland biopsy in patients screened for Sj\u00f6gren's syndrome","volume":"64","author":"Van Mello","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.revmed.2019.03.329_bib0415","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/ard.2010.144782","article-title":"Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sj\u00f6gren's syndrome","volume":"70","author":"Theander","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.revmed.2019.03.329_bib0420","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.revmed.2019.03.329_bib0425","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","article-title":"Defining disease activity states and clinically meaningful improvement in primary Sj\u00f6gren's syndrome with EULAR primary Sj\u00f6gren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)","volume":"75","author":"Seror","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.revmed.2019.03.329_bib0430","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.revmed.2019.03.329_bib0435","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.revmed.2017.09.004","article-title":"Severity of illness index in autoimmune diseases: Have there any usefulness in medical practice?","volume":"38","author":"Saunier","year":"2017","journal-title":"Rev Med Interne"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0440","first-page":"362","article-title":"A multicentre study of 95\u00a0biopsy-proven cases of renal disease in primary Sj\u00f6gren's syndrome","volume":"56","author":"Jasiek","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.revmed.2019.03.329_bib0445","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/BOR.0000000000000096","article-title":"EULAR-SS task force group. Advances in the understanding and treatment of systemic complications in Sj\u00f6gren's syndrome","volume":"26","author":"Brito-Zer\u00f3n","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"10.1016\/j.revmed.2019.03.329_bib0450","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/acr.21991","article-title":"European League Against Rheumatism Sj\u00f6gren's Syndrome Disease Activity Index and European League Against Rheumatism Sj\u00f6gren's Syndrome Patient-Reported Index: a complete picture of primary Sj\u00f6gren's syndrome patients","volume":"65","author":"Seror","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.revmed.2019.03.329_bib0455","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","article-title":"Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921\u00a0Spanish patients (GEAS-SS Registry)","volume":"53","author":"Ramos-Casals","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.revmed.2019.03.329_bib0460","doi-asserted-by":"crossref","first-page":"e59868","DOI":"10.1371\/journal.pone.0059868","article-title":"Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sj\u00f6gren's syndrome. Data at enrollment in the prospective ASSESS cohort","volume":"8","author":"Gottenberg","year":"2013","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0465","first-page":"102","article-title":"How immunological profile drives clinical phenotype of primary Sj\u00f6gren's syndrome at diagnosis: analysis of 10,500\u00a0patients (Sj\u00f6gren Big Data Project)","volume":"36\u00a0Suppl 112","author":"Brito-Zer\u00f3n","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0470","first-page":"198","article-title":"Phenotyping Sj\u00f6gren's syndrome: towards a personalised management of the disease","volume":"36\u00a0Suppl1 12","author":"Brito-Zer\u00f3n","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.revmed.2019.03.329_bib0475","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202863","article-title":"Health-related utility values of patients with primary Sj\u00f6gren's syndrome and its predictors","volume":"73","author":"Lendrem","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0480","first-page":"450","article-title":"Rate, risk factors and causes of mortality in patients with Sj\u00f6gren's syndrome: a systematic review and meta-analysis of cohort studies","volume":"55","author":"Singh","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2019.03.329_bib0485","doi-asserted-by":"crossref","first-page":"647507","DOI":"10.1155\/2014\/647507","article-title":"Clinical course, prognosis, and cause of death in primary Sj\u00f6gren's syndrome","volume":"2014","author":"Horvath","year":"2014","journal-title":"J Immunol Res"},{"issue":"5","key":"10.1016\/j.revmed.2019.03.329_bib0490","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/rheumatology\/ket427","article-title":"Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients","volume":"53","author":"Baldini","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0495","first-page":"121","article-title":"Severe, life-threatening phenotype of primary Sj\u00f6gren's syndrome: clinical characterisation and outcomes in 1580\u00a0patients (GEAS-SS Registry)","volume":"36\u00a0Suppl 112","author":"Flores-Ch\u00e1vez","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.revmed.2019.03.329_bib0500","doi-asserted-by":"crossref","first-page":"888","DOI":"10.7326\/0003-4819-89-6-888","article-title":"Increased risk of lymphoma in sicca syndrome","volume":"89","author":"Kassan","year":"1978","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.revmed.2019.03.329_bib0505","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2014-206418","article-title":"Systemic activity and mortality in primary Sj\u00f6gren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045\u00a0patients","volume":"75","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0510","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bjh.13192","article-title":"Sj\u00f6gren Syndrome-associated lymphomas: an update on pathogenesis and management","volume":"168","author":"Nocturne","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.revmed.2019.03.329_bib0515","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/art.39534","article-title":"Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sj\u00f6gren's Syndrome","volume":"68","author":"Tomi","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"8","key":"10.1016\/j.revmed.2019.03.329_bib0520","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","article-title":"Malignant lymphoma in primary Sj\u00f6gren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sj\u00f6gren's Syndrome","volume":"42","author":"Voulgarelis","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.revmed.2019.03.329_bib0525","first-page":"278","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren's Syndrome","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"4","key":"10.1016\/j.revmed.2019.03.329_bib0530","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/1529-0131(200004)43:4<908::AID-ANR24>3.0.CO;2-K","article-title":"Salivary gland lymphomas in patients with Sj\u00f6gren's syndrome may frequently develop from rheumatoid factor B cells","volume":"43","author":"Martin","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.revmed.2019.03.329_bib0535","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.39002","article-title":"Stereotypic rheumatoid factors that are frequently expressed in mucosa-associated lymphoid tissue-type lymphomas are rare in the labial salivary glands of patients with Sj\u00f6gren's syndrome","volume":"67","author":"Bende","year":"2015","journal-title":"Arthritis Rheumatology (Hoboken, NJ)"},{"issue":"9","key":"10.1016\/j.revmed.2019.03.329_bib0540","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/art.40528","article-title":"Ectopic Germinal Center-Like Structures in Minor Salivary Gland Biopsy Tissue Predict Lymphoma Occurrence in Patients With Primary Sj\u00f6gren's Syndrome","volume":"70","author":"S\u00e8ne","year":"2018","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"10","key":"10.1016\/j.revmed.2019.03.329_bib0545","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1136\/annrheumdis-2017-211290","article-title":"Germinal centres in diagnostic labial gland biopsies of patients with primary Sj\u00f6gren's syndrome are not predictive for parotid MALT lymphoma development","volume":"76","author":"Haacke","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.revmed.2019.03.329_bib0550","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.3899\/jrheum.131527","article-title":"Evaluation of germinal center-like structures and B cell clonality in patients with primary Sj\u00f6gren syndrome with and without lymphoma","volume":"41","author":"Johnsen","year":"2014","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.revmed.2019.03.329_bib0555","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/annrheumdis-2013-204634","article-title":"The prognostic value of routinely performed minor salivary gland assessments in primary Sj\u00f6gren's syndrome","volume":"73","author":"Risselada","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.revmed.2019.03.329_bib0560","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","article-title":"BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands","volume":"52","author":"Quartuccio","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"17","key":"10.1016\/j.revmed.2019.03.329_bib0565","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","article-title":"Overexpression of the Cytokine BAFF and Autoimmunity Risk","volume":"376","author":"Steri","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2019.03.329_bib0570","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar1884","article-title":"No evidence for an association between the -871T\/C promoter polymorphism in the B-cell-activating factor gene and primary Sj\u00f6gren's syndrome","volume":"8","author":"Gottenberg","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"25","key":"10.1016\/j.revmed.2019.03.329_bib0575","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1182\/blood-2013-05-503383","article-title":"Germline and somatic genetic variations of TNFAIP3\u00a0in lymphoma complicating primary Sjogren's syndrome","volume":"122","author":"Nocturne","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.revmed.2019.03.329_bib0580","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2015-207731","article-title":"Germline variation of TNFAIP3\u00a0in primary Sj\u00f6gren's syndrome-associated lymphoma","volume":"75","author":"Nocturne","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2019.03.329_bib0585","doi-asserted-by":"crossref","DOI":"10.1002\/art.40829","article-title":"Usefulness of 18F-FDG Positron Emission Tomography (PET) for the diagnosis of lymphoma in primary Sj\u00f6gren's syndrome","author":"Keraen","year":"2019","journal-title":"Arthritis Rheumatism"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0590","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/bjh.15120","article-title":"Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sj\u00f6gren syndrome (pSS)","volume":"184","author":"Demaria","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.revmed.2019.03.329_bib0595","doi-asserted-by":"crossref","first-page":"e0116189","DOI":"10.1371\/journal.pone.0116189","article-title":"Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients","volume":"10","author":"Papageorgiou","year":"2015","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.revmed.2019.03.329_bib0600","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","article-title":"Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj\u00f6gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01\u00a0Study Group","volume":"159","author":"Vivino","year":"1999","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1016\/j.revmed.2019.03.329_bib0605","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.45.9.732","article-title":"Cyclosporin A (CyA) in primary Sj\u00f6gren's syndrome: a double blind study","volume":"45","author":"Drosos","year":"1986","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0610","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sj\u00f6gren Syndrome: The JOQUER Randomized Clinical Trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.revmed.2019.03.329_bib0615","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1177\/0961203396005001081","article-title":"Treatment of primary Sj\u00f6gren's syndrome with hydroxychloroquine: a retrospective, open-label study","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.revmed.2019.03.329_bib0620","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","article-title":"Hydroxychloroquine treatment for primary Sj\u00f6gren's syndrome: a two year double blind crossover trial","volume":"52","author":"Kruize","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2019.03.329_bib0625","unstructured":"Clinical Efficacy of Leflunomide\/Hydroxychloroquine Combination Therapy in Patients with Primary Sjogren's Syndrome: Results of a Placebo-Controlled Double-Blind Randomized Clinical Trial [Internet]. ACR Meeting Abstracts, 2018. Disponible sur\u00a0: https:\/\/acrabstracts.org\/abstract\/clinical-efficacy-of-leflunomide-hydroxychloroquine-combination-therapy-in-patients-with-primary-sjogrens-syndrome-results-of-a-placebo-controlled-double-blind-randomized-clinical-trial\/ [consult\u00e9 le 17\u00a0Dec 2018]."},{"issue":"8","key":"10.1016\/j.revmed.2019.03.329_bib0630","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nrrheum.2016.100","article-title":"Treatment of primary Sj\u00f6gren syndrome","volume":"12","author":"Saraux","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0635","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren's syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.revmed.2019.03.329_bib0640","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.revmed.2019.03.329_bib0645","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.revmed.2019.03.329_bib0650","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.revmed.2019.03.329_bib0655","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sj\u00f6gren's Syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0660","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.revmed.2019.03.329_bib0665","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2019.03.329_bib0670","unstructured":"The Novel Anti-CD40\u00a0Monoclonal Antibody CFZ533\u00a0Shows Beneficial Effects in Patients with Primary Sj\u00f6gren's Syndrome: A Phase IIa Double-Blind, Placebo-Controlled Randomized Trial [Internet]. ACR Meeting Abstracts, 2017. Disponible sure\u00a0: https:\/\/acrabstracts.org\/abstract\/the-novel-anti-cd40-monoclonal-antibody-cfz533-shows-beneficial-effects-in-patients-with-primary-sjogrens-syndrome-a-phase-iia-double-blind-placebo-controlled-randomized-trial\/ [consult\u00e9 le 27\u00a0Fev 2019]."},{"issue":"5","key":"10.1016\/j.revmed.2019.03.329_bib0675","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0049-0172(96)80019-9","article-title":"Clinicopathological factors relating malignant lymphoma with Sj\u00f6gren's syndrome","volume":"25","author":"Anaya","year":"1996","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0680","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj\u00f6gren's syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.revmed.2019.03.329_bib0685","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00296-014-3051-x","article-title":"Identification of lymphoma predictors in patients with primary Sj\u00f6gren's syndrome: a systematic literature review and meta-analysis","volume":"35","author":"Nishishinya","year":"2015","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.revmed.2019.03.329_bib0690","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","article-title":"Lymphoma and other malignancies in primary Sj\u00f6gren's syndrome: a cohort study on cancer incidence and lymphoma predictors","volume":"65","author":"Theander","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.revmed.2019.03.329_bib0695","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/art.1780390508","article-title":"Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sj\u00f6gren's syndrome","volume":"39","author":"Tzioufas","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.revmed.2019.03.329_bib0350","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.semarthrit.2011.04.006","article-title":"Risk, predictors, and clinical characteristics of lymphoma development in primary Sj\u00f6gren's syndrome","volume":"41","author":"Solans-Laqu\u00e9","year":"2011","journal-title":"Semin Arthritis Rheum"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319304242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319304242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:40:34Z","timestamp":1759336834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866319304242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0248866319304242"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2019.03.329","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualit\u00e9s dans le syndrome de Sj\u00f6gren primitif\u00a0: aspects cliniques et th\u00e9rapeutiques","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2019.03.329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}